Jade Biosciences JBIO
NASDAQ JBIO
$14.13 -0.05 (-0.35%)
As of: Sep 30, 2026 · 3:06 PM EDT

Jade Biosciences (JBIO) Convertible Debt (2024)

Updated

Jade Biosciences' Convertible Debt was $107.6 million in Q4 2024.

Analysis

Jade Biosciences (JBIO) Convertible Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Jade Biosciences 901.23 Mn 901.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 107.60 Mn
API Access

Jade Biosciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=JBIO&period=max&api_key=YOUR_API_KEY